Evidence map›Paper›PMID 37634215›Full record

ArticleMedical oncology (Northwood, London, England)2023

EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway.

Nan Ding, Abin You, Senxia Zhao, Hu Yang, Chunping Lai, Feng Ye

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nan Ding *Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Abin You *Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Senxia ZhaoDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Hu YangDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Chunping LaiThe Third Clinical Medical College, Fujian Medical University, FuZhou, China.
Feng YeDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, School of Medicine, the First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China. yefengdoctor@xmu.edu.cn.ORCID http://orcid.org/0000-0001-8254-755X
Fujian Medical University · CNFirst Affiliated Hospital of Xiamen University · CN

Funding

Health Youth Scientific Research Project of Fujian Province 2020QNB057Health Youth Scientific Research Project of Fujian Province 2021QNB015Natural Science Foundation of Fujian Province 2020J011238Natural Science Foundation of Fujian Province 2021J05291Natural Science Foundation of Fujian Province 2022J05304start-up funds for the introduction of talents from the First Affiliated Hospital of Xiamen University 3502Z20214ZD3010
6 · The paper itself

Abstract

EZH2, a highly conserved histone methyltransferase, plays an essential role in tumorigenesis and development. The inhibitor of EZH2 tazemetostat has been approved to treat metastatic or locally advanced epithelioid sarcoma and recurrent or refractory follicular lymphoma. However, the effect of tazemetostat alone or in combination with other drugs in esophageal cancer has not been reported. In this study, we found that EZH2 was highly expressed in esophageal cancer at both mRNA and protein levels through transcriptomic and proteomic analyses. Furthermore, the results of CCK8, colony formation, cell cycle and cell apoptosis assays revealed that tazemetostat exerted an antitumour effect on esophageal cancer cells. Mechanistically, RNA-sequencing analysis of the tazemetostat-treated cells and vehicle-treated ones suggested that tazemetostat mainly inhibited the c-Myc signaling pathway and its targets, which was validated by western blotting. JQ-1, an inhibitor of bromodomain 4, was proven to attenuate c-Myc signaling in tumors. Thus, a therapeutic strategy based on tazemetostat in combination with JQ-1 is promising. The results demonstrated that tazemetostat and JQ-1 had a synergistic effect in vitro and in vivo for esophageal cancer.

Indexed as

Esophageal NeoplasmsSignal TransductionBenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinEnzyme InhibitorsHumansMorpholinesProteomicsProto-Oncogene Proteins c-mycPyridonesBenzamidesBiphenyl CompoundsEnhancer of Zeste Homolog 2 ProteinEnzyme InhibitorsEZH2 protein, humanMorpholinesProto-Oncogene Proteins c-mycPyridonestazemetostatc-MycEsophageal cancerEZH2JQ-1Synergistic effectTazemetostat

Identifiers

PMID37634215
OpenAlexW4386204198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.